Hematocrit above 30% Incontinuous Ambulatory Peritoneal Dialysis Patients Treated Withery Thropoiet in is Harmful

Keown P.A. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. In: Gurland H.J. , Moran J. , Samtleben W. , Scigalla P. , Wieczorek L. , eds. Erythropoietin in renal and non-renal anaemias. Contrib Nephrot 1991; 88: 81–6.

Samtleben W. , Baldamus C.A. , Bommer J. Indications and contraindications for recombinant human erythropoiet in treatment. In: Baldamus C.A. , Scigalla P. , Wieczorek L. , Koch K.M. , eds. Erythropoietin: from molecular structure to clinical application. Contrib Nephrol 1989; 76: 193–200.

Eschbach J.W. , Egrie J.C. , Downing M.R. The safety of epoetin-alpha: Results of clinical trials in the United States. In: Gurland H.J. , Moran J. , Samtleben W. , Scigalla P. , Wieczorek L. , eds. Erythropoietin in renal and non-renal anaemias. Contrib Nephrol 1991; 88: 7280.

Charra B. , Calemard E. , Ruffet M. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 128691.

Macdougall I.C. , Davies M.E. , Hut ton R.D. Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. Br J Haemtol 1991; 77: 550–8.

Korbet S.M. , Vonech E.F. , Firanel C.A. The effect of hematocrit on peritoneal transport. Am J Kidney Dis 1991; XVIII:5: 573–8.

Maynard A. Harsh choices for UK NHS. Scrip. 1990; 1568: 7–8.

Suzuki M. , Hirasawa Y. , Hirashima K. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (ChugaiJ in Japanese patients with end-stage renal disease. In: Baldamus C.A. , Scigalla P. , Wieczorek L. , Koch K.M. , eds. Erythropoietin: from molecular structure of clinical application. Contrib Nephrol 1989; 76: 179–92.